Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Glooko, Diasend merge to deliver premier diabetes management platform

Glooko and Diasend have merged into a unified company, in a bid to deliver enhanced diabetes management and analytics platforms for patients and clinicians.

In a move that will accelerate the overarching mission to make diabetes management easier worldwide, Glooko and Diasend today announced they have merged into a unified company.

“This is a big day for us – we are thrilled to come together to be able to deliver products and services that will offer even more value to patients and healthcare providers around the world,” says Rick Altinger, CEO of Glooko, Inc.

“This is without a doubt the best possible scenario for our two companies, as well as for patients and the care teams that serve them. From our standpoint, this means adding even more functionality to an already very strong technical platform,” says Anders Sonesson, CEO of Diasend AB.

As a combined entity, the new company now serves 4,000 diabetes clinics in 23 countries across 15 languages, impacting tens of millions of people with diabetes.

The joint platform downloads data from more than 160 different devices – including glucose meters, insulin pumps, continuous glucose monitors (CGMs) and activity trackers, in total covering over 95% of diabetes devices used worldwide.

Together the joint solution enables support for people with diabetes during and in-between doctor visits, as well as in-office diabetes data uploads and analytics.

The products also provide smartphone enabled self-management and a population health platform that supports diabetes coaches around the world.

The two companies, which have chosen to unite under the Glooko name, have recently raised $8M in equity financing, led by global venture capital firm Canaan Partners, to accelerate integration and sales efforts.

 Other investors include Social Capital, Samsung Ventures and Yogen Dalal, Glooko’s founder and partner emeritus at venture capital firm Mayfield fund.

Glooko, based in Mountain View, CA and Diasend, in Gothenburg, Sweden, have both spent recent years perfecting their respective take on the optimal solution for diabetes data management. Recent product announcements show this.

 Glooko’s recently announced  Glooko Advise product line is focused on leveraging diabetes data to deliver personalized medicine recommendations to patients and care teams. Diasend’s recent announcement focused on enabling Abbott’s Freestyle LibreLink patients to see their glucose data alongside pump data.

As a combined entity, these and other product delivery initiatives will not only continue, but will also be optimized and accelerated through the larger combined team.

Diasend simplifies life for people with diabetes and facilitates the work of their health care providers by optimizing diabetes data management.

The company’s comprehensive and market leading solution involves transmitting, storing and analyzing data from more than 140 different glucose meters, insulin pumps, CGM systems and leading activity trackers – allowing patients and caregivers to easily access the exact same information.

Glooko is the leading remote patient monitoring platform for diabetes and is trusted by the world’s leaders in diabetes care.

Glooko provides an FDA-cleared, HIPAA-compliant Web and Mobile application designed to improve health outcomes for people with diabetes, which in turn reduces costs for payers and the healthcare system.